Table 2.

Responses and survival analysis according to different histological subtypes.

Histologic subtype	Patients	Best response							Median PFSb (95% CI)	1-year OS Rate (%)
		CR	PR	SD	PD	NAa	ORR (%)	DCR (%)
Liposarcoma	17 (35)	0	2 (12)	15 (88)	0	0	12	100	12.5 (7.1–18.0)	100.0
WDLS	4 (8)	0	1 (25)	3 (75)	0	0	25	100	19.1 (3.0–35.2)	100.0
DDLS	11 (22)	0	1 (9)	10 (91)	0	0	9	100	9.0 (4.9–13.2)	100.0
Myxoid liposarcoma	2 (4)	0	0	2 (100)	0	0	0	100	NE (NE)	100.0
Leiomyosarcoma	15 (31)	0	2 (13)	12 (80)	1 (7)	0	13	93	7.7 (5.7–9.6)	100.0
Synovial sarcoma	4 (8)	1 (25)	0	1 (25)	1 (25)	1 (25)	25	50	19.1 (0–48.8)	100.0
Fibrosarcoma	3 (6)	0	1 (33)	2 (67)	0	0	33	100	3.6 (3.5–3.6)	100.0
Unclassified sarcoma	3 (6)	0	1 (33)	2 (67)	0	0	33	100	NE (NE)	100.0
Other subtypesc	7 (14)	0	1 (14)	6 (86)	0	0	14	100	7.8 (0–18.5)	85.7
Overall	49 (100)	1 (2)	7 (14)	38 (78)	2 (4)	1 (2)	16 (95% CI 7–30)	94 (95% CI 83–99)	9.1 (5.7–12.5)	98.0

Data are n (%), n/N (%) and median survival (95% CI). Responses were assessed in accordance with Response Evaluation Criteria in Solid Tumours (RECIST, version 1.1). Only confirmed responses were included.

CR = complete response. PR = partial response. SD = stable disease. PD = progressive disease. NA = not assessed. ORR = objective response rate. DCR = disease control rate. PFS = progression-free survival. CI = confidence interval. OS = overall survival. WDLS = well-differentiated liposarcoma. DDLS = dedifferentiated liposarcoma. NE = not evaluable.

^aThe patient who lost to follow-up before the first scheduled post-baseline evaluation.

^bThe median PFS for anlotinib maintenance treatment.

^cOther subtypes: angiosarcoma, undifferentiated pleomorphic sarcoma, low-grade myofibroblastic sarcoma, sclerosing epithelioid fibrosarcoma, epithelioid sarcoma, epithelioid haemangioendothelioma and extraskeletal myxoid chondrosarcoma.